Trials / No Longer Available
No Longer AvailableNCT03702036
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- —
Summary
Compassionate use access to molibresib/GSK525762 for eligible participant with NUT Midline Carcinoma; indication is a seriously debilitating or life-threatening disease.
Detailed description
Investigational Product GSK525762 is an orally bioavailable small molecule that is a potent inhibitor of the binding of BET proteins to acetylated histones. Binding of GSK525762 induces squamous differentiation and inhibits proliferation of patient-derived NMC cell lines both in culture and in murine xenografts. Compassionate use access to molibresib is restricted to patients with confirmed diagnosis of NUT Midline Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | molibresib | molibresib 20 mg will be supplied for compassionate use for the identified individual subject. |
Timeline
- First posted
- 2018-10-10
- Last updated
- 2020-04-13
Source: ClinicalTrials.gov record NCT03702036. Inclusion in this directory is not an endorsement.